A Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor210]

Clinical Trial ID NCT02108652

PubWeight™ 17.56^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02108652

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.	Lancet	2016	5.79
2	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.	Lancet	2016	2.84
3	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.	Oncoimmunology	2015	1.06
4	Clinical impact of checkpoint inhibitors as novel cancer therapies.	Drugs	2014	0.99
5	Cancer immunotherapy in clinical practice -- the past, present, and future.	Chin J Cancer	2014	0.98
6	Muscle-invasive urothelial bladder cancer: an update on systemic therapy.	Ther Adv Urol	2015	0.98
7	Targeted therapies in bladder cancer: an overview of in vivo research.	Nat Rev Urol	2015	0.94
8	A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736.	Transl Lung Cancer Res	2014	0.81
9	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.	Oncologist	2015	0.81
10	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer.	Bladder Cancer	2016	0.79
11	Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.	Clin Genitourin Cancer	2015	0.79
12	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.	Clin Cancer Res	2015	0.78
13	Immune checkpoint blockade therapy for bladder cancer treatment.	Investig Clin Urol	2016	0.78
14	Novel molecular targets for urothelial carcinoma.	Expert Opin Ther Targets	2015	0.76
15	Clinical Trials Corner.	Bladder Cancer	2016	0.75